{"product_id":"gild-business-model-canvas","title":"Gilead Sciences, Inc. (GILD): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas of Gilead Sciences, Inc. gives you a research-based view of a global biopharma business built on HIV leadership, long-acting prevention, oncology, inflammation, and global access through \u003cstrong\u003e120+\u003c\/strong\u003e country HIV licensees. You'll see how the company creates value through Phase 3 development, AI-enabled drug discovery, global manufacturing, and FDA trial collaboration, then captures it through HIV, oncology, COVID-19, inflammation, and international licensing revenue, while serving HIV treatment and prevention patients, oncology patients and oncologists, liver disease patients, and global access markets through hospitals, specialist prescribers, specialty pharmacies, and direct commercial teams, with major resources including \u003cstrong\u003e17,000+\u003c\/strong\u003e employees, \u003cstrong\u003e$10.0B\u003c\/strong\u003e in cash and securities, and cost drivers such as R\u0026amp;D, manufacturing, \u003cstrong\u003e$32.0B\u003c\/strong\u003e in capital investments, licensing payments, and litigation.\u003c\/p\u003e\u003ch2\u003eGilead Sciences, Inc. - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eGenesis Therapeutics\u003c\/strong\u003e: \u003cstrong\u003e$35 million\u003c\/strong\u003e upfront; \u003cstrong\u003eup to $1.5 billion\u003c\/strong\u003e in potential milestone payments.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eJanssen\u003c\/strong\u003e: \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e royalty buyout.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHIV licensees\u003c\/strong\u003e: \u003cstrong\u003e120+\u003c\/strong\u003e countries.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFDA and trial collaborators\u003c\/strong\u003e: \u003cstrong\u003e1\u003c\/strong\u003e FDA approval in \u003cstrong\u003e2022\u003c\/strong\u003e; \u003cstrong\u003e2\u003c\/strong\u003e Phase 3 studies; \u003cstrong\u003e5,338\u003c\/strong\u003e participants in PURPOSE 1.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003ePartner\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNumber or Amount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eScope\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenesis Therapeutics\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$35 million\u003c\/strong\u003e; \u003cstrong\u003eup to $1.5 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ecollaboration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanssen\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eroyalty buyout\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV licensees\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e120+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ecountries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e; \u003cstrong\u003e2022\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eapproval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial collaborators\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e; \u003cstrong\u003e5,338\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePhase 3 studies; PURPOSE 1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003eGenesis Therapeutics: \u003cstrong\u003e$35 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eGenesis Therapeutics: \u003cstrong\u003eup to $1.5 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eJanssen: \u003cstrong\u003e$1.1 billion\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eHIV licensees: \u003cstrong\u003e120+\u003c\/strong\u003e countries\u003c\/li\u003e\n\u003cli\u003eFDA and trials: \u003cstrong\u003e1\u003c\/strong\u003e approval; \u003cstrong\u003e2022\u003c\/strong\u003e; \u003cstrong\u003e2\u003c\/strong\u003e Phase 3 studies; \u003cstrong\u003e5,338\u003c\/strong\u003e participants\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eGilead Sciences, Inc. - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003e3\u003c\/strong\u003e late-2025 activity clusters define Gilead Sciences, Inc.: HIV R\u0026amp;D, oncology R\u0026amp;D, and inflammation R\u0026amp;D. The commercial engine is built around \u003cstrong\u003e1\u003c\/strong\u003e-tablet daily oral therapy, \u003cstrong\u003e2\u003c\/strong\u003e-injection-per-year prevention, and \u003cstrong\u003e1\u003c\/strong\u003e-infusion cell therapy.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eActivity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNumeric anchor\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eLate-2025 business role\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet daily; \u003cstrong\u003e2\u003c\/strong\u003e injections per year\u003c\/td\u003e\n\u003ctd\u003eRegimen simplification and adherence\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e CAR-T products; \u003cstrong\u003e1\u003c\/strong\u003e antibody-drug conjugate\u003c\/td\u003e\n\u003ctd\u003eCell therapy and tumor-targeted treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflammation R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCymaBay Therapeutics acquisition and seladelpar development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhase 3 development\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e PURPOSE studies\u003c\/td\u003e\n\u003ctd\u003eLenacapavir prevention program\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI-enabled discovery\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e; \u003cstrong\u003e1\u003c\/strong\u003e collaboration\u003c\/td\u003e\n\u003ctd\u003eSmall-molecule target and lead generation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial launch execution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 18, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYeztugo FDA approval and rollout\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHIV, oncology, inflammation R\u0026amp;D\u003c\/strong\u003e: Gilead Sciences, Inc. runs \u003cstrong\u003e3\u003c\/strong\u003e therapeutic-area workstreams. In HIV, the commercial model centers on \u003cstrong\u003e1\u003c\/strong\u003e-tablet daily treatment and \u003cstrong\u003e2\u003c\/strong\u003e-dose-per-year prevention. In oncology, the model splits between \u003cstrong\u003e2\u003c\/strong\u003e approved CAR-T therapies and \u003cstrong\u003e1\u003c\/strong\u003e antibody-drug conjugate, which means both individualized cell manufacturing and scalable biologics development matter. In inflammation, the \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e CymaBay Therapeutics acquisition added seladelpar to the portfolio and expanded the company's non-HIV growth base.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePhase 3 clinical development\u003c\/strong\u003e: the late-stage pipeline depends on \u003cstrong\u003e3\u003c\/strong\u003e PURPOSE studies for lenacapavir prevention: PURPOSE 1, PURPOSE 2, and PURPOSE 3. That matters because phase 3 is the last large test before approval, so it is where efficacy, safety, and dosing convenience are converted into label claims and pricing power.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e PURPOSE studies for lenacapavir prevention\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e injections per year for the commercial prevention regimen\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e regulatory package moving from phase 3 data to FDA review\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI-enabled drug discovery\u003c\/strong\u003e: in \u003cstrong\u003e2024\u003c\/strong\u003e, Gilead Sciences, Inc. added \u003cstrong\u003e1\u003c\/strong\u003e AI collaboration with Genesis Therapeutics. The strategic value is in faster target selection, faster hit finding, and fewer failed compounds before phase 1, which lowers the cost of each approved molecule if the platform keeps producing viable candidates.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal manufacturing scale-up\u003c\/strong\u003e: Gilead Sciences, Inc. operates across \u003cstrong\u003e3\u003c\/strong\u003e manufacturing archetypes: oral small molecules, antibody-drug conjugates, and autologous cell therapy. Cell therapy is the most complex because it requires \u003cstrong\u003e1\u003c\/strong\u003e patient-specific lot per infusion, while oral HIV products require wide global supply for \u003cstrong\u003e1\u003c\/strong\u003e-tablet daily use and long-acting prevention products require synchronized release planning for \u003cstrong\u003e2\u003c\/strong\u003e injections per year.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct or platform\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNumeric feature\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOperational meaning\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet, \u003cstrong\u003e1\u003c\/strong\u003e time daily\u003c\/td\u003e\n\u003ctd\u003eHigh-volume oral supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYeztugo\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e injections per year\u003c\/td\u003e\n\u003ctd\u003eLong-acting HIV prevention launch\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e dosing days in a \u003cstrong\u003e21\u003c\/strong\u003e-day cycle\u003c\/td\u003e\n\u003ctd\u003eOncology launch and cycle management\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYescarta\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e infusion\u003c\/td\u003e\n\u003ctd\u003eAutologous cell-therapy manufacturing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTecartus\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e infusion\u003c\/td\u003e\n\u003ctd\u003eAutologous cell-therapy manufacturing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCommercial launch execution\u003c\/strong\u003e: \u003cstrong\u003eJune 18, 2025\u003c\/strong\u003e is the key launch date for Yeztugo. That launch turns a \u003cstrong\u003e2\u003c\/strong\u003e-injection-per-year prevention regimen into a marketable product, so execution depends on physician education, access, reimbursement, and supply availability from day \u003cstrong\u003e1\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology execution\u003c\/strong\u003e: Gilead Sciences, Inc. manages \u003cstrong\u003e2\u003c\/strong\u003e CAR-T launches and \u003cstrong\u003e1\u003c\/strong\u003e ADC launch at the same time, which makes manufacturing slots, site onboarding, and channel inventory more important than in a standard oral-drug launch. The commercial task is not just selling therapy; it is also keeping \u003cstrong\u003e1\u003c\/strong\u003e personalized infusion chain and \u003cstrong\u003e1\u003c\/strong\u003e global oncology supply chain moving without delays.\u003c\/p\u003e\n\u003ch2\u003eGilead Sciences, Inc. - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e5\u003c\/strong\u003e branded assets, \u003cstrong\u003e17,000+\u003c\/strong\u003e global employees, and \u003cstrong\u003e$10.0B\u003c\/strong\u003e in cash and securities are the main late-2025 resources behind Gilead Sciences, Inc.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey resource\u003c\/th\u003e\n\u003cth\u003eReal-life number or amount\u003c\/th\u003e\n\u003cth\u003eLate-2025 relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet once daily; \u003cstrong\u003e$13.4B\u003c\/strong\u003e 2024 sales\u003c\/td\u003e\n\u003ctd\u003eHIV treatment anchor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYeztugo\u003c\/td\u003e\n\u003ctd\u003eFDA approval on \u003cstrong\u003eJune 18, 2025\u003c\/strong\u003e; \u003cstrong\u003e2\u003c\/strong\u003e doses per year\u003c\/td\u003e\n\u003ctd\u003eHIV prevention asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrodelvy\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e U.S. breast cancer indications\u003c\/td\u003e\n\u003ctd\u003eOncology asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeklury\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e-day outpatient regimen\u003c\/td\u003e\n\u003ctd\u003eAntiviral asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLivdelzi\u003c\/td\u003e\n\u003ctd\u003eFDA approval on \u003cstrong\u003eAugust 14, 2024\u003c\/strong\u003e; \u003cstrong\u003e1\u003c\/strong\u003e daily oral therapy\u003c\/td\u003e\n\u003ctd\u003eLiver disease asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eBiktarvy and Yeztugo give Gilead Sciences, Inc. a mix of \u003cstrong\u003e1\u003c\/strong\u003e-pill daily treatment and \u003cstrong\u003e2\u003c\/strong\u003e-dose yearly prevention. That combination is unusual in HIV because it links an established treatment brand with a long-acting prevention brand.\u003c\/p\u003e\n\n\u003cp\u003eTrodelvy, Veklury, and Livdelzi add \u003cstrong\u003e3\u003c\/strong\u003e more named assets across oncology, virology, and liver disease. The set of \u003cstrong\u003e5\u003c\/strong\u003e brands reduces reliance on a single product line, even though Biktarvy alone delivered \u003cstrong\u003e$13.4B\u003c\/strong\u003e in 2024 sales.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCorporate resource\u003c\/th\u003e\n\u003cth\u003eReal-life number or amount\u003c\/th\u003e\n\u003cth\u003eLate-2025 relevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal workforce\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17,000+\u003c\/strong\u003e employees\u003c\/td\u003e\n\u003ctd\u003eCommercial, clinical, manufacturing, and research capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFunding for trials, launches, and acquisitions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFoster City center\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e333 Lakeside Drive\u003c\/strong\u003e, Foster City, CA \u003cstrong\u003e94404\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eHeadquarters and research hub\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI labs\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e Foster City site\u003c\/td\u003e\n\u003ctd\u003eData and discovery work tied to the same campus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e17,000+\u003c\/strong\u003e global employees\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$10.0B\u003c\/strong\u003e cash and securities\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e333 Lakeside Drive\u003c\/strong\u003e, Foster City, CA \u003cstrong\u003e94404\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e Foster City headquarters and research site\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e Yeztugo doses per year\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e-day Veklury outpatient regimen\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eGilead Sciences, Inc. - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eLeading HIV treatment portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e7\u003c\/strong\u003e marketed HIV medicines: Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, Truvada, and Sunlenca.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eActive ingredients\u003c\/th\u003e\n\u003cth\u003eDosing\u003c\/th\u003e\n\u003cth\u003eNumeric value proposition\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiktarvy\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet once daily\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e-tablet regimen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDescovy\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet once daily\u003c\/td\u003e\n\u003ctd\u003eOral treatment and PrEP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenvoya\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet once daily\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e-tablet regimen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOdefsey\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet once daily\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e-tablet regimen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSymtuza\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet once daily\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e-tablet regimen\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTruvada\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet once daily\u003c\/td\u003e\n\u003ctd\u003eOral treatment and PrEP\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSunlenca\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003estarter dosing plus \u003cstrong\u003e2\u003c\/strong\u003e injections per year\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e-month dosing interval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e-tablet regimens: Biktarvy, Descovy, Genvoya, Odefsey, Symtuza, Truvada\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e-drug regimens: Biktarvy, Odefsey\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e-drug regimens: Genvoya, Symtuza\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e-drug regimens: Descovy, Truvada\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e-drug long-acting regimen: Sunlenca\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLong-acting HIV prevention\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePURPOSE 1: \u003cstrong\u003e2,134\u003c\/strong\u003e participants, \u003cstrong\u003e0\u003c\/strong\u003e HIV infections in the lenacapavir arm, \u003cstrong\u003e99.9%\u003c\/strong\u003e reported incidence reduction.\u003c\/p\u003e\n\u003cp\u003ePURPOSE 2: \u003cstrong\u003e2,180\u003c\/strong\u003e participants, \u003cstrong\u003e2\u003c\/strong\u003e HIV infections in the lenacapavir arm, \u003cstrong\u003e96%\u003c\/strong\u003e reported incidence reduction.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e-month prevention interval\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e phase 3 prevention trials\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e infections in the PURPOSE 1 lenacapavir arm\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e infections in the PURPOSE 2 lenacapavir arm\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology options for solid tumors\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTrodelvy: \u003cstrong\u003e2\u003c\/strong\u003e U.S. solid-tumor indications.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eTrial\u003c\/th\u003e\n\u003cth\u003ePopulation\u003c\/th\u003e\n\u003cth\u003eOverall survival\u003c\/th\u003e\n\u003cth\u003eProgression-free survival\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASCENT\u003c\/td\u003e\n\u003ctd\u003eMetastatic triple-negative breast cancer\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e12.1\u003c\/strong\u003e months vs \u003cstrong\u003e6.7\u003c\/strong\u003e months\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5.6\u003c\/strong\u003e months vs \u003cstrong\u003e1.7\u003c\/strong\u003e months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTROPiCS-02\u003c\/td\u003e\n\u003ctd\u003eHR-positive\/HER2-negative metastatic breast cancer\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e14.4\u003c\/strong\u003e months vs \u003cstrong\u003e11.2\u003c\/strong\u003e months\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e5.5\u003c\/strong\u003e months vs \u003cstrong\u003e4.0\u003c\/strong\u003e months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e approved metastatic breast cancer settings\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e pivotal datasets for the solid-tumor platform\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e12.1\u003c\/strong\u003e months and \u003cstrong\u003e14.4\u003c\/strong\u003e months median overall survival in key trials\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eNew inflammation therapy entry\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCymaBay Therapeutics acquisition value: \u003cstrong\u003e$4.3 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eAdded assets: \u003cstrong\u003e1\u003c\/strong\u003e late-stage inflammation\/liver program.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.3 billion\u003c\/strong\u003e transaction value\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e acquired lead asset\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e new therapeutic area added through acquisition\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal access through licensing\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVoluntary licensing footprint: \u003cstrong\u003e127\u003c\/strong\u003e countries.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e127\u003c\/strong\u003e countries in the access territory\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e licensing-based access model\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eGilead Sciences, Inc. - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eGilead Sciences, Inc. builds customer relationships around long-duration treatment, specialist prescribers, and access support. The model depends on chronic use, with \u003cstrong\u003e3\u003c\/strong\u003e core therapeutic areas and \u003cstrong\u003e2\u003c\/strong\u003e approved CAR-T therapies that need close follow-up, referral networks, and safety monitoring.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCustomer relationship pillar\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life numeric anchor\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWho it reaches\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhy it matters\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChronic care and adherence support\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e3\u003c\/strong\u003e core therapeutic areas\u003c\/td\u003e\n\u003ctd\u003ePatients with HIV, liver disease, and cancer\u003c\/td\u003e\n\u003ctd\u003eSupports long-term treatment persistence and repeat prescribing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist physician engagement\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e approved CAR-T therapies\u003c\/td\u003e\n\u003ctd\u003eInfectious disease physicians, hepatologists, oncologists, and cell therapy centers\u003c\/td\u003e\n\u003ctd\u003eCreates high-touch, specialist-led prescribing relationships\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term patient treatment access\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e U.S.-approved HIV PrEP medicines\u003c\/td\u003e\n\u003ctd\u003ePatients needing prevention and ongoing viral suppression\u003c\/td\u003e\n\u003ctd\u003eSupports reimbursement help, continuation, and affordability access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVoluntary licensing partnerships\u003c\/td\u003e\n\u003ctd\u003eNonexclusive licensing model\u003c\/td\u003e\n\u003ctd\u003eGeneric manufacturers and public health systems in lower-income markets\u003c\/td\u003e\n\u003ctd\u003eWidens access while keeping tighter control in higher-income markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory and safety oversight\u003c\/td\u003e\n\u003ctd\u003eREMS-linked therapies\u003c\/td\u003e\n\u003ctd\u003ePrescribers, patients, regulators, and treatment centers\u003c\/td\u003e\n\u003ctd\u003eBuilds trust and reduces safety-related treatment disruption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eChronic care and adherence support\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGilead Sciences, Inc. relies on relationships that last for years, not weeks. That is especially true in HIV and hepatitis B, where treatment is often long term and adherence matters every day. Support usually centers on refill continuity, insurance navigation, copay help, and patient education. In this model, a missed dose can weaken outcomes, so relationship quality affects both health results and revenue durability. The company's chronic-care base is also reinforced by treatment switching, where physicians move patients to newer regimens with simpler dosing, fewer interactions, or better tolerability. That keeps the customer relationship active even after the first prescription.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLong-duration therapy increases the value of retention over single-sale transactions.\u003c\/li\u003e\n\u003cli\u003eAdherence support matters because chronic viral disease management depends on consistent dosing.\u003c\/li\u003e\n\u003cli\u003eInsurance and access help can reduce treatment interruptions.\u003c\/li\u003e\n\u003cli\u003eSwitching to newer regimens keeps the prescriber relationship with Gilead Sciences, Inc. in place.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eSpecialist physician engagement\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGilead Sciences, Inc. does not depend on broad consumer marketing. It depends on specialist doctors who diagnose, start, and monitor complex therapies. In HIV, that means infectious disease specialists and primary care doctors with HIV experience. In liver disease, it means hepatologists and gastroenterologists. In oncology and cell therapy, it means cancer specialists and centers that can handle infusion, monitoring, and toxicity management. The relationship is technical because the therapies are technical. For CAR-T, the physician relationship extends beyond prescribing to referral, preparation, infusion, and follow-up. That makes the doctor, not the patient alone, a core part of the customer relationship.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSpecialists drive initiation, switching, and long-term continuation.\u003c\/li\u003e\n\u003cli\u003eCell therapy depends on trained centers rather than mass retail distribution.\u003c\/li\u003e\n\u003cli\u003ePost-treatment monitoring keeps the relationship active after the infusion date.\u003c\/li\u003e\n\u003cli\u003eClinical education has direct business value because it shapes adoption in high-complexity care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eLong-term patient treatment access\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLong-term access is central to Gilead Sciences, Inc. because many of its therapies are used continuously or preventively. The company has \u003cstrong\u003e2\u003c\/strong\u003e U.S.-approved HIV PrEP medicines, which makes access, affordability, and adherence support part of the product relationship itself. Patients often need help with insurance approval, pharmacy access, and out-of-pocket cost pressure. For chronic therapy, a good customer relationship is not just a sale; it is the ability to keep the patient on therapy without interruption. That is why reimbursement support, specialty pharmacy coordination, and patient assistance are commercially important. If access breaks down, the patient can stop therapy, and the relationship weakens immediately.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e U.S.-approved HIV PrEP medicines support a prevention-based access model.\u003c\/li\u003e\n\u003cli\u003eAffordability help protects persistence in chronic treatment.\u003c\/li\u003e\n\u003cli\u003eSpecialty pharmacy coordination reduces friction at the point of fill.\u003c\/li\u003e\n\u003cli\u003eAccess continuity matters because long-term treatment is more valuable than a one-time prescription.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eVoluntary licensing partnerships\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGilead Sciences, Inc. uses voluntary licensing as a relationship tool in lower-income markets. The model is nonexclusive, which means it can work through multiple generic manufacturers rather than a single commercial channel. That matters in HIV and other antiviral access because broad supply can lower barriers to treatment in countries where branded pricing would limit uptake. These partnerships also reduce tension with public health systems by making access part of the business model instead of an afterthought. In practice, the relationship is not with one end customer alone; it is with governments, procurement systems, generic producers, and global health buyers. That makes the company's access strategy a network relationship, not a direct retail one.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNonexclusive licensing broadens supply capacity.\u003c\/li\u003e\n\u003cli\u003eGeneric partners improve reach in lower-income markets.\u003c\/li\u003e\n\u003cli\u003ePublic health buyers become part of the customer network.\u003c\/li\u003e\n\u003cli\u003eAccess terms can support both treatment scale and reputational trust.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRegulatory and safety oversight\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGilead Sciences, Inc. operates under heavy regulatory and safety oversight because its therapies can be long term, high risk, or highly specialized. Safety management includes label updates, adverse-event reporting, post-marketing studies, and restricted-use controls where needed. CAR-T therapies are a clear example of this relationship type because they depend on trained treatment centers and formal monitoring rules. The company's relationship with regulators is also part of the customer model because compliance affects whether a product can stay on the market and how easily physicians can use it. In this setting, trust is built through safety data, not marketing language.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eREMS-linked products require stricter use and monitoring rules.\u003c\/li\u003e\n\u003cli\u003eAdverse-event reporting keeps regulators and physicians connected to the product lifecycle.\u003c\/li\u003e\n\u003cli\u003ePost-marketing safety work supports ongoing market access.\u003c\/li\u003e\n\u003cli\u003eSafety controls matter more for advanced therapies than for simple retail medicines.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eGilead Sciences, Inc. - Canvas Business Model: Channels\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospital and specialist prescribers\u003c\/strong\u003e are the main channel for Gilead Sciences, Inc.'s infused oncology, cell therapy, and IV antiviral products. Yescarta and Tecartus are delivered as \u003cstrong\u003e1\u003c\/strong\u003e-time CAR-T infusions after cell collection and manufacturing, so the real gatekeepers are authorized treatment centers, not retail pharmacies. Trodelvy is given on days \u003cstrong\u003e1\u003c\/strong\u003e and \u003cstrong\u003e8\u003c\/strong\u003e of each \u003cstrong\u003e21\u003c\/strong\u003e-day cycle, which keeps oncologists and infusion suites at the center of access, scheduling, and monitoring. Veklury uses a \u003cstrong\u003e5\u003c\/strong\u003e-day inpatient course or a \u003cstrong\u003e3\u003c\/strong\u003e-day outpatient course, so hospital formulary placement and infusion capacity directly affect use.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eProduct examples\u003c\/th\u003e\n\u003cth\u003eReal-life numeric feature\u003c\/th\u003e\n\u003cth\u003eChannel role\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital and specialist prescribers\u003c\/td\u003e\n\u003ctd\u003eYescarta, Tecartus, Trodelvy, Veklury\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e-time infusion; \u003cstrong\u003e5\u003c\/strong\u003e-day course; \u003cstrong\u003e3\u003c\/strong\u003e-day course; days \u003cstrong\u003e1\u003c\/strong\u003e and \u003cstrong\u003e8\u003c\/strong\u003e in a \u003cstrong\u003e21\u003c\/strong\u003e-day cycle\u003c\/td\u003e\n\u003ctd\u003eControls access through hospitals, infusion centers, and authorized treatment sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail and specialty pharmacies\u003c\/td\u003e\n\u003ctd\u003eBiktarvy, Descovy, Sunlenca\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1\u003c\/strong\u003e tablet daily; \u003cstrong\u003e2\u003c\/strong\u003e oral loading days; \u003cstrong\u003e6\u003c\/strong\u003e-month maintenance injection\u003c\/td\u003e\n\u003ctd\u003eHandles chronic refills, prior authorization, and adherence support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal licensing networks\u003c\/td\u003e\n\u003ctd\u003eHIV access and generic supply arrangements\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e130\u003c\/strong\u003e countries\u003c\/td\u003e\n\u003ctd\u003eExtends reach into markets beyond direct commercial coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect commercial sales teams\u003c\/td\u003e\n\u003ctd\u003eOral HIV, oncology, antiviral, and cell therapy portfolios\u003c\/td\u003e\n\u003ctd\u003eApprovals in \u003cstrong\u003e2016\u003c\/strong\u003e, \u003cstrong\u003e2017\u003c\/strong\u003e, \u003cstrong\u003e2018\u003c\/strong\u003e, \u003cstrong\u003e2020\u003c\/strong\u003e, \u003cstrong\u003e2022\u003c\/strong\u003e, and \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eConnects products to the right physician, site, payer, and pharmacy channel\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical and medical affairs\u003c\/td\u003e\n\u003ctd\u003eMedical science, congress activity, post-marketing support\u003c\/td\u003e\n\u003ctd\u003ePhase \u003cstrong\u003e3\u003c\/strong\u003e and phase \u003cstrong\u003e4\u003c\/strong\u003e evidence\u003c\/td\u003e\n\u003ctd\u003eBuilds scientific credibility and supports adoption in practice\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHospital and specialist prescribers\u003c\/strong\u003e matter because they control the most complex products in the portfolio. CAR-T treatment requires a specialized site, a treatment pathway, and coordination across collection, shipping, and infusion. That makes the channel expensive to enter but hard for competitors to copy. It also means one approved therapy can still have uneven uptake if enough sites are not trained or accredited. For academic writing, this channel shows how a biopharma company can sell a product only after it builds a clinical service network around it.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eYescarta and Tecartus use a \u003cstrong\u003e1\u003c\/strong\u003e-infusion administration model after manufacturing.\u003c\/li\u003e\n\u003cli\u003eTrodelvy uses dosing on days \u003cstrong\u003e1\u003c\/strong\u003e and \u003cstrong\u003e8\u003c\/strong\u003e in a \u003cstrong\u003e21\u003c\/strong\u003e-day cycle.\u003c\/li\u003e\n\u003cli\u003eVeklury uses a \u003cstrong\u003e5\u003c\/strong\u003e-day or \u003cstrong\u003e3\u003c\/strong\u003e-day IV regimen depending on setting.\u003c\/li\u003e\n\u003cli\u003eThese products depend on hospital inventory, specialist training, and treatment-site activation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRetail and specialty pharmacies\u003c\/strong\u003e are the main channel for Gilead Sciences, Inc.'s chronic oral medicines. Biktarvy and Descovy are both \u003cstrong\u003e1\u003c\/strong\u003e-tablet, once-daily regimens, so the channel is built around refill persistence rather than one-time dispensing. Sunlenca adds a different pattern: \u003cstrong\u003e2\u003c\/strong\u003e oral loading doses on days \u003cstrong\u003e1\u003c\/strong\u003e and \u003cstrong\u003e2\u003c\/strong\u003e, then \u003cstrong\u003e1\u003c\/strong\u003e injection every \u003cstrong\u003e6\u003c\/strong\u003e months. That type of schedule pushes the prescription through specialty pharmacy workflows, benefit checks, and long-term adherence support.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eBiktarvy and Descovy fit routine retail and specialty pharmacy refill models.\u003c\/li\u003e\n\u003cli\u003eSunlenca fits specialty pharmacy and clinic coordination because it is tied to a \u003cstrong\u003e6\u003c\/strong\u003e-month dosing interval.\u003c\/li\u003e\n\u003cli\u003eOral HIV products create recurring prescription volume, which is different from the \u003cstrong\u003e1\u003c\/strong\u003e-time hospital model used for CAR-T therapies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal licensing networks\u003c\/strong\u003e expand access beyond Gilead Sciences, Inc.'s owned commercial channels. Gilead Sciences, Inc. markets medicines in more than \u003cstrong\u003e130\u003c\/strong\u003e countries, so licensing matters for markets where direct sales coverage is weaker or not practical. In channel terms, licensing changes the route to market from a branded sale through a field force to a multi-country supply structure. That usually lowers per-unit economics but broadens patient reach, which is important for large-volume public health products.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect commercial sales teams\u003c\/strong\u003e are the layer that makes the channel work in daily practice. They connect the product to the physician, the hospital account, the pharmacy hub, and the payer. The portfolio they support spans first approvals in \u003cstrong\u003e2016\u003c\/strong\u003e, \u003cstrong\u003e2017\u003c\/strong\u003e, \u003cstrong\u003e2018\u003c\/strong\u003e, \u003cstrong\u003e2020\u003c\/strong\u003e, \u003cstrong\u003e2022\u003c\/strong\u003e, and \u003cstrong\u003e2024\u003c\/strong\u003e, so the sales motion has to handle mature oral therapies, newer oncology drugs, and highly specialized cell therapy products at the same time. That mix requires different account plans for each product class.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eOral products need refill continuity and payer access work.\u003c\/li\u003e\n\u003cli\u003eInfused oncology products need site-level ordering, scheduling, and reimbursement support.\u003c\/li\u003e\n\u003cli\u003eCell therapies need treatment-center activation and multi-step care coordination.\u003c\/li\u003e\n\u003cli\u003eDifferent approval years mean different lifecycle needs inside the same field organization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical and medical affairs\u003c\/strong\u003e support the channel by turning data into use. Their role is not just education; it is access creation. Phase \u003cstrong\u003e3\u003c\/strong\u003e evidence supports label use, while phase \u003cstrong\u003e4\u003c\/strong\u003e follow-up shows how a medicine performs after approval. For hospital and specialist channels, this matters because prescribers want practical evidence on administration, toxicity management, and patient selection before they adopt a new therapy. This is especially important for products that require a center-based treatment model rather than a simple retail prescription.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003ePhase \u003cstrong\u003e3\u003c\/strong\u003e evidence supports adoption by specialists and hospital committees.\u003c\/li\u003e\n\u003cli\u003ePhase \u003cstrong\u003e4\u003c\/strong\u003e follow-up supports long-term safety and real-world use.\u003c\/li\u003e\n\u003cli\u003eMedical affairs also supports dosing, handling, and referral-pathway training.\u003c\/li\u003e\n\u003cli\u003eFor cell therapy, scientific support is tied directly to site readiness and patient flow.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eGilead Sciences, Inc. - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\n\u003cp\u003eHIV treatment patients are the largest and most durable segment. \u003cstrong\u003e39.9 million\u003c\/strong\u003e people were living with HIV in 2023, and \u003cstrong\u003e30.7 million\u003c\/strong\u003e were receiving antiretroviral therapy, so the core market is a repeat-prescription population with long treatment duration.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e39.9 million\u003c\/strong\u003e people living with HIV in 2023.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e30.7 million\u003c\/strong\u003e people on antiretroviral therapy in 2023.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e630,000\u003c\/strong\u003e AIDS-related deaths in 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer segment\u003c\/td\u003e\n\u003ctd\u003eLatest real-world size\u003c\/td\u003e\n\u003ctd\u003eCommercial meaning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV treatment patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e39.9 million\u003c\/strong\u003e living with HIV; \u003cstrong\u003e30.7 million\u003c\/strong\u003e on antiretroviral therapy\u003c\/td\u003e\n\u003ctd\u003eChronic therapy, regimen switching, long duration of use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV prevention patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.3 million\u003c\/strong\u003e new HIV infections in 2023\u003c\/td\u003e\n\u003ctd\u003ePre-exposure prophylaxis demand and adherence-sensitive use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology patients and oncologists\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20 million\u003c\/strong\u003e new cancer cases and \u003cstrong\u003e9.7 million\u003c\/strong\u003e cancer deaths in 2022\u003c\/td\u003e\n\u003ctd\u003eSpecialist prescribing, hospital access, biomarker-driven care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver disease patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e254 million\u003c\/strong\u003e chronic hepatitis B cases and \u003cstrong\u003e50 million\u003c\/strong\u003e chronic hepatitis C cases in 2022\u003c\/td\u003e\n\u003ctd\u003eAntiviral treatment and cure-focused demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal access markets\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e120\u003c\/strong\u003e countries in access coverage structures; \u003cstrong\u003e25.9 million\u003c\/strong\u003e people living with HIV in sub-Saharan Africa in 2023\u003c\/td\u003e\n\u003ctd\u003ePublic-sector procurement and lower-price volume markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eHIV prevention patients are defined by incidence rather than prevalence. \u003cstrong\u003e1.3 million\u003c\/strong\u003e new HIV infections in 2023 set the size of the prevention opportunity, and long-acting prevention matters because it reduces daily-pill dependence.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e1.3 million\u003c\/strong\u003e new HIV infections in 2023.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e120\u003c\/strong\u003e countries in access coverage structures.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e25.9 million\u003c\/strong\u003e people living with HIV in sub-Saharan Africa in 2023.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eOncology patients and oncologists form a specialist segment with large disease volume. \u003cstrong\u003e20 million\u003c\/strong\u003e new cancer cases and \u003cstrong\u003e9.7 million\u003c\/strong\u003e cancer deaths in 2022 create demand for hospital and clinic delivery, while oncologists remain the main prescribers.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e20 million\u003c\/strong\u003e new cancer cases in 2022.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e9.7 million\u003c\/strong\u003e cancer deaths in 2022.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e core burden metrics define the segment: incidence and mortality.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eLiver disease patients remain relevant through chronic hepatitis B and hepatitis C. \u003cstrong\u003e254 million\u003c\/strong\u003e people were living with chronic hepatitis B in 2022, and \u003cstrong\u003e50 million\u003c\/strong\u003e were living with chronic hepatitis C in 2022, which keeps antiviral demand tied to screening, treatment, and follow-up.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e254 million\u003c\/strong\u003e chronic hepatitis B cases in 2022.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e50 million\u003c\/strong\u003e chronic hepatitis C cases in 2022.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e major viral liver diseases anchor the segment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eGlobal access markets are sized by geography and disease burden. \u003cstrong\u003e120\u003c\/strong\u003e countries in access coverage structures and \u003cstrong\u003e25.9 million\u003c\/strong\u003e people living with HIV in sub-Saharan Africa in 2023 show why lower-income markets matter for volume, pricing, and public-sector procurement.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e120\u003c\/strong\u003e countries in access coverage structures.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e25.9 million\u003c\/strong\u003e people living with HIV in sub-Saharan Africa in 2023.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e6\u003c\/strong\u003e generic manufacturers were included in one lenacapavir access structure.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eGilead Sciences, Inc. - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$4.8B\u003c\/strong\u003e in research and development expense and \u003cstrong\u003e$6.2B\u003c\/strong\u003e in cost of product sales.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$32.0B\u003c\/strong\u003e in cumulative capital investments.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCost structure item\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003ePeriod\u003c\/th\u003e\n\u003cth\u003eDisclosure basis\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D and clinical trials\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003eresearch and development expense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and supply chain\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.2B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003ecost of product sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital investments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$32.0B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ecumulative\u003c\/td\u003e\n\u003ctd\u003eU.S. investment figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing and royalty payments\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003epublic filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLitigation and settlement costs\u003c\/td\u003e\n\u003ctd\u003eNot separately disclosed\u003c\/td\u003e\n\u003ctd\u003e2023\u003c\/td\u003e\n\u003ctd\u003epublic filing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.8B\u003c\/strong\u003e R\u0026amp;D expense\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$6.2B\u003c\/strong\u003e cost of product sales\u003c\/li\u003e\n \u003cli\u003e\n\u003cstrong\u003e$32.0B\u003c\/strong\u003e cumulative capital investments\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eGilead Sciences, Inc. - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRevenue stream\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024 amount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMain disclosed components\u003c\/strong\u003e\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV product sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBiktarvy $13.4 billion; Descovy $3.0 billion; Genvoya $2.2 billion; Odefsey $1.1 billion; Symtuza $0.8 billion; Truvada $0.6 billion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology product sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.6 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYescarta $1.6 billion; Trodelvy $1.3 billion; Tecartus $0.7 billion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOVID-19 treatment sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.8 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eVeklury $0.8 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInflammation therapy sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.1 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJyseleca $0.1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational licensing revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.0 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eroyalty, contract and other revenue $1.0 billion\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eHIV product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBiktarvy $13.4 billion\u003c\/li\u003e\n\u003cli\u003eDescovy $3.0 billion\u003c\/li\u003e\n\u003cli\u003eGenvoya $2.2 billion\u003c\/li\u003e\n\u003cli\u003eOdefsey $1.1 billion\u003c\/li\u003e\n\u003cli\u003eSymtuza $0.8 billion\u003c\/li\u003e\n\u003cli\u003eTruvada $0.6 billion\u003c\/li\u003e\n\u003cli\u003eTotal $21.1 billion\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eYescarta $1.6 billion\u003c\/li\u003e\n\u003cli\u003eTrodelvy $1.3 billion\u003c\/li\u003e\n\u003cli\u003eTecartus $0.7 billion\u003c\/li\u003e\n\u003cli\u003eTotal $3.6 billion\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCOVID-19 treatment sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eVeklury $0.8 billion\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInflammation therapy sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eJyseleca $0.1 billion\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eInternational licensing revenue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eroyalty, contract and other revenue $1.0 billion\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601599950997,"sku":"gild-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/gild-business-model-canvas.png?v=1740177769","url":"https:\/\/dcf-model.com\/es\/products\/gild-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}